comparison between pregnancy outcome of in vitro fertilization (assisted reproductive technology ) with and without Gonadotropin-releasing hormone agonist

Frozen Thawed Embryo Transfer Cycles: A Comparison of Pregnancy Outcomes with and without Prior Pituitary Suppression by Gonadotropin-releasing hormone Agonists

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017052834184N1

Enrollment

200

Registered

2017-08-07

Start date

2012-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: in vitro fertilization. Condition 2: infertility. Admission for harvesting or implantation of ova inability to achieve a pregnancy

Interventions

Intervention 1: Participanpatients in group A received GnRH agonist prior to ovulation induction.0.5 mg of Busereline acetate (a GnRH agonist) (Suprefact, Hoechst AG, Germany) was injected subcutaneou

Treatment - Drugs

patients in group B had steroid manipulation and routine IVF regimen without prior down-regulation of the pituitary

Participanpatients in group A received GnRH agonist prior to ovulation induction.0.5 mg of Busereline acetate (a GnRH agonist) (Suprefact, Hoechst AG, Germany) was injected subcutaneously daily starti

Eligibility

Sex/Gender

Female

Age

20 Years to 39 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: Documented infertility of any cause;Aged 20-39 years; Couples undergoing ART with their own gametes;Women stimulated with a long GnRH agonist protocol of IVF (for group A);Couples having frozen embryo available for transfer exclusion criteria: Age > 39 years; High grade endometriosis;Existence of myoma or adhesion in uterus;Body mass index (BMI) more than 29 kg/m2 or less than 18 kg/m2;Oocyte donation cycles

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pregnancy outcome. Timepoint: since 16 days post transfer until delivery. Method of measurement: beta hCG, Ultrasound.	—

Secondary

Measure	Time frame
Clinical pregnancy. Timepoint: 5 weeks after transfer date. Method of measurement: observation of intrauterine gestational sac during ultrasound examination 5 weeks after transfer date.;Chemical pregnancy. Timepoint: 16 days following thawed embryo transfer. Method of measurement: Serum ßHCG level > 10 IU per L.;Ongoing pregnancy. Timepoint: 12 weeks after transfer date. Method of measurement: presence of intrauterine fetal heart motion.;Implantation rate. Timepoint: 9 weeks post transfer. Method of measurement: number of gestational sacs with fetal pole detected using vaginal ultrasound to the number of transferred embryos.;Miscarriage rate. Timepoint: under the 20th week of gestation. Method of measurement: ultrasound and beta hCG.	—

Measure

Time frame

Clinical pregnancy. Timepoint: 5 weeks after transfer date. Method of measurement: observation of intrauterine gestational sac during ultrasound examination 5 weeks after transfer date.;Chemical pregnancy. Timepoint: 16 days following thawed embryo transfer. Method of measurement: Serum ßHCG level > 10 IU per L.;Ongoing pregnancy. Timepoint: 12 weeks after transfer date. Method of measurement: presence of intrauterine fetal heart motion.;Implantation rate. Timepoint: 9 weeks post transfer. Method of measurement: number of gestational sacs with fetal pole detected using vaginal ultrasound to the number of transferred embryos.;Miscarriage rate. Timepoint: under the 20th week of gestation. Method of measurement: ultrasound and beta hCG.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohre Chitsazi

Shiraz University of Medical Sciences

z.chitsazi@yahoo.com+98 917 714 4835

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026